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Identity 
Other names: DKFZp686I2148, MAP2A, MAP2B, 
MAP2C, 
HGNC (Hugo): MAP2 
Location: 2q34 
Note 
The protein encoded by this gene plays a role in 
dendrite morphogenesis in the vertebrate central 
nervous system. This function is accomplished by 
regulating microtubule stability and preventing the 
depolymerization of microtubules by stiffening them. It 
is known to have a number of distinctive isoforms. 
DNA/RNA 
Description 
The DNA consists of three or four tandem repeats that 
code for 31 amino acid long residues. 
The gene contains 15 exons and has a size of 310064 
base pairs. Alternative splicing of this gene gives rise to 
a large variety of transcripts and isoforms. 
Transcription 
Four transcription variants have been characterized. 
- MAP2 Isoform 5 (NM_001039538.1 --> 
NP_001034627.1): The difference in this isoform is 
characterized by the 5' UTR which results in the 
production of a longer protein when compared to 
isoform 2. 
- MAP2 Isoform 1 (NM_002374.3 --> NP_002365.3): 
This isoform is thought to be the longest encoded an  
contains three alternative in-frame exons when 
compared to isoform 2. The tubulin binding and MAP2 
projection domains are conserved. 
- MAP2 Isoform 2 (NM_031845.2 --> NP_114033.2): 
This is the shortest transcript. 
- MAP2 Isoform 4 (NM_031847.2 --> NP_114035.2): 
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Variant 5 mRNA Gene 
 
Exon  Start End Length Start End Length 
1 1 230 230 1 230 230 
2 231 280 50 83546 83595 50 
3 281 345 65 155990 156054 65 
4 346 422 77 201007 201083 77 
5 423 713 291 229096 229386 291 
6 714 827 114 254526 254639 114 
7 828 905 78 256704 256781 78 
8 906 967 62 276231 276292 62 
9 968 1138 171 280404 280574 171 
10 1139 1286 148 281534 281681 148 
11 1287 1627 341 285868 286208 341 
12 1628 1720 93 299549 299641 93 
13 1721 1802 82* 301633 301744 112* 
14 1803 1915 113 305804 305916 113 
15 1916 5844 3929 306136 310064 3929 
TOTAL LENGTH : 5844* 
   
 
Variant 1 mRNA Gene 
 
Exon Start End Length Start End Length 
1 1 77 77 155633 155709 77 
2 78 142 65 155990 156054 65 
3 143 219 77 201007 201083 77 
4 220 510 291 229096 229386 291 
5 511 624 114 254526 254639 114 
6 625 702 78 256704 256781 78 
7 703 4428 3726 268579 272304 3726 
8 4429 4635 207 272496 272702 207 
9 4636 4770 135 272871 273005 135 
10 4771 4832 62 276231 276292 62 
11 4833 4980 148 281534 281681 148 
12 4981 5321 341 285868 286208 341 
13 5322 5403 82 301663 301744 82 
14 5404 5516 113 305804 305916 113 
15 5517 9445 3929 306136 310064 3929 
TOTAL LENGTH : 9445 
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Variant 4 mRNA Gene 
 
Exon  Start End Length Start End Length 
1 1 77 77 155633 155709 77 
2 78 142 65 155990 156054 65 
3 143 219 77 201007 201083 77 
4 220 510 291 229096 229386 291 
5 511 624 114 254526 254639 114 
6 625 702 78 256704 256781 78 
7 703 764 62 276231 276292 62 
8 765 912 148 281534 281681 148 
9 913 1253 341 285868 286208 341 
10 1254 1346 93 299549 299641 93 
11 1347 1428 82 301663 301744 82 
12 1429 1541 113 305804 305916 113 
13 1542 5470 3929 306136 310064 3929 
TOTAL LENGTH : 5470 
   
 
Variant 2 mRNA Gene 
  
Exon Star End Length Start End Length 
1 1 77 77 155633 155709 77 
2 78 142 65 155990 156054 65 
3 143 219 77 201007 201083 77 
4 220 510 291 229096 229386 291 
5 511 624 114 254526 254639 114 
6 625 702 78 256704 256781 78 
7 703 764 62 276231 276292 62 
8 765 912 148 281534 281681 148 
9 913 1253 341 285868 286208 341 
10 1254 1335 82 301663 301744 82 
11 1336 1448 113 305804 305916 113 
12 1449 5377 3929 306136 310064 3929 
TOTAL LENGTH : 5377 
   




MAP2 is an approximately 1827 amino acid long 
protein with an estimated molecular weight of 200 kDa, 
with the exact molecular weight varying by isoform. 
Four isoforms have been characterized, but additional 
ones are thought to exist. The protein undergoes post-
translational phosphorylation upon DNA damage. The 
phosphorylation is hypothesized to be catalyzed by 
ATM or ATR. In the rat brain, the various isoforms 
were characterized at different stages of development - 
isoform MAP2B is found throughout rat brain 
development, while MAP2A appears towards the end 
of the second week of post-natal life. MAP2C is found 
during the early development of the brain, but after 
maturation is only found in the neural cells of the 
retina, olfactory bulb and the cerebellum. 
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Description 
MAP2 is a mostly unfolded protein that changes 
conformation upon binding to its target molecule. A 
domain near its carboxyl terminus enables MAP2 
protein to bind to the microtubules. A 31 amino acid 
long repeating motif is characteristic of this protein. 
However, it is found that this motif is not sufficient by 
itself to bind to microtubules. Two contiguous 
sequences on either end of this repeating structure on 
both the amino and carboxyl ends enable the binding of 
this protein to the microtubules. A proline rich domain 
on the amino end is thought to be especially crucial in 
this process. The protein is known to have three tubulin 
binding domains spanning residues 1160-1691; 1692-
1722; 1723-1754. The protein also has a projection 
domain which extends from residues 377-1505. All 
isoforms have a conserved C-terminal domain which 
contain tubulin binding repeats and a conserved N-
terminal projection domain. The projection domain 
varies in size across isoforms, has a net negative charge 
and exerts a long range repulsive force. This gives a 
potential mechanism that explains how MAP2 regulates 
the spacing between microtubules. 
Expression 
MAP2 plays a major role in dendrite morphogenesis 
and is normally expressed in neurons. It has also been 
reported to be ectopically expressed in several cancers 
including melanoma and breast cancer. 
Localisation 
MAP2 mRNAs were found in the avian neuronal cell 
body cytoplasm; however the protein was found 
localized to the dendrites in mammals (Cristofanilli et 
al., 2004). The same report shows that avian neuronal 
MAP2 mRNA lacks a dendritic targeting element in its 
3' UTR. Local expression within dendrites is 
hypothesized to be more suited to regulate need based 
synthesis. Tubulin, a protein expressed in both axons 
and dendrites is known to be expressed in the 
cytoplasm of the cell body showing that location 
specific expression of proteins is important to the 
maintenance of polarity of the neural cells. 
Function 
MAP2 stabilizes microtubule bundling and stiffening 
through the interactions of several weak binding sites to 
the microtubules on the protein. The strength of 
bundling of microtubules is directly correlated to the 
strength of the binding to MAP2. This enables the 
microtubules to support outgrowth from the cells. 
When MAP2 was expressed by transfection in non 
neuronal cells, it induced the rearrangement of the 
microtubules into long bundles. These bundles enabld 
outgrowths from the non neuronal cells. 
Experiments done with knockout mice show that the 
role of MAP2 in neuronal morphogenesis may be 
redundant (Teng et al., 2001). Single knockouts of 
MAP2 did not show any severe phenotypes but 
simultaneous knockouts of MAP2 and MAP1B died in 
the prenatal stage (Teng et al., 2001). There are sev ral 
reports of functional redundancy amongst the MAP 
proteins. 
Homology 
A microtubule associated protein with similar function 
to MAP2 is known to be expressed in the rat (Rattus 
norvegicus), chicken (Gallus gallus) and lizard (Anolis 
carolinensis) with varying levels of sequence 
homology. In the fruit fly, the tau gene seems to 
perform a similar function. 
Mutations 
Note 
35 SNPs associated with MAP2 have been identified. 
The CAGs, which are a set of trinucleotide sequences 
starting at exon 1 of the MAP2 gene on the 5' UTR 
region, are conserved in the general population 




It has been found by Soltani et al. that primary 
melanomas that express the MAP2 gene have a lower 
rate of metastasis later on than primary melanomas that 
do not express the MAP2 gene. It has been proposed 
that MAP2 expression disrupts microtubule formation 
in cancer cells and interferes with cell cycle 
progression. 
Multiple sclerosis lesions 
Note 
Novel transcript of MAP2 that expresses exon 13 is 
shown to be up-regulated in multiple sclerosis lesion  
(Shafit-Zagardo et al., 1998). They proposed that tis




Abnormal hyperphosphorylation of several tau 
proteins, MAP1 and MAP2 have been implicated in 
leading to progressive degeneration and loss of 
connectivity between neurons. 
Various diseases 
Note 
MAP2 expression is altered in response to various 
illnesses and thus is used as a marker in the diagnosis 
of many specific illnesses and especially as a marker of 
neuronal differentiation. 
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